Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration

Miravant Pharmaceuticals660 enrolled

Overview

The purpose of this study is to confirm the efficacy and safety of rostaporfin (PHOTREX) photodynamic therapy (PDT) in the treatment of classic and occult subfoveal choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

660

Conditions

Macular Degeneration

Interventions

Photrex (rostaporfin)DRUG

Eligibility

Sex: ALLMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patients with age greater than or equal to 50 years with at least one subfoveal CNV membrane secondary to AMD that can be demonstrated by fluorescein angiography.

Locations (4)

Multiple Investigators

Sofia, Bulgaria

RECRUITING

Multiple Investigators

Brno-Bohunice, Olomouc, Praha, Czechia

RECRUITING

Multiple Investigators

Warsaw, Bydgoszcz, Lubin, Poland

RECRUITING

Outcomes

Primary Outcomes

Visual Acuity

Secondary Outcomes

Angiographic changes

Central Contacts

Miravant Pharmaceuticals

CONTACT

1-800-685-2959 ctinfo@miravant.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.